Approved Therapeutics/Drug Candidates,
Bioactive Small Molecule Alphabetical Index,
Bioactive Small Molecules,
Cell Biology,
Cell Signaling and Neuroscience,
Chemical Structure,
Chromatography,
Drugs of Abuse,
Forensic and Veterinary Standards,
M,
Neurobiology,
Neuroscience,
Neurotransmission (Obesity),
Obesity Research,
Pharmaceuticals, Illicit Drugs & Alcohol,
Pharmacologicals,
Stimulants,
Teva
More...
InChI Key
TWXDDNPPQUTEOV-FVGYRXGTSA-N
drug control
USDEA Schedule II; Home Office Schedule 2; stupéfiant; kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)
solubility
H2O: soluble
ethanol: soluble
originator
Teva
Description:
Biochem/physiol Actions
Sympathomimetic with more potent central effects than amphetamine. It is transported into terminals via the monoamine transporters and induces release of dopamine, norepinephrine, epinephrine, and serotonin. Dopamine release is important for the addictive properties of methamphetamine while norepinephrine and epinephrine release are important for the cardiovascular effects. Serotonin neurotoxin.
Features and Benefits
This compound was developed by Teva. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Safety:
Symbol
GHS06
Signal word
Danger
Hazard statements
H300-H336
Precautionary statements
Missing Phrase - N15.00950417
Personal Protective Equipment
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges